---
title: Gene Editing for <em>CEP290</em>-Associated Retinal Degeneration
date: '2024-05-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38709228/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240506181206&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: The safety profile and improvements in photoreceptor function
  after EDIT-101 treatment in this small phase 1-2 study support further research
  of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due
  to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine
  and others; BRILLIANCE ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: The safety profile and improvements in photoreceptor function after EDIT-101 treatment in this small phase 1-2 study support further research of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine and others; BRILLIANCE ClinicalTrials.gov number, ...